Published • loading... • Updated
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
- Akeso, Inc. has dosed the first patient in a Phase II trial evaluating the combination of AK146D1 and ivonescimab for advanced breast cancer treatment.
- The study targets first-line treatment of HR+/HER2- breast cancer and triple-negative breast cancer using Akeso's IO2.0 + ADC2.0 regimen.
- AK146D1 has shown strong antitumor effects and good safety in early trials.
- Ivonescimab is a PD-1/VEGF bispecific antibody that has demonstrated better clinical results than PD-1 inhibitors in several Phase III trials.
Insights by Ground AI
39 Articles
39 Articles
The Herald-Dispatch+38 Reposted by 38 other sources
Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer
HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) evaluating AK146D1, the Company's internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (bsADC),…
Coverage Details
Total News Sources39
Leaning Left5Leaning Right5Center24Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
15%
C 70%
15%
Factuality
To view factuality data please Upgrade to Premium
